Study guide
10.1 High-Risk Obstetric Assessment & Hypertensive Disorders of Pregnancy
IBSC CCP-C Certified Critical Care Paramedic Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Strategy
1.1 About the CCP-C Exam 1.2 CCP-C Study Strategy & Exam Tactics
2 Chapter 2: Transport and Safety (Part 1)
2.1 Crew Resource Management & Sterile Cockpit Rule 2.2 Transport Risk Assessment & Mission Decision-Making 2.3 Aircraft and Ground Transport Safety Protocols
3 Chapter 2: Transport and Safety (Part 2)
2.4 Environmental Transport Stressors & Gas Laws 2.5 Transport Equipment Management & Post-Mission Operations
4 Chapter 3: Airway, Anesthesia, and Analgesics (Part 1)
3.1 Advanced Airway Assessment & Difficult Airway Identification 3.2 Rapid Sequence Induction (RSI) - Pretreatment & Induction Agents 3.3 Neuromuscular Blockade - Depolarizing vs Non-Depolarizing Agents 3.4 Post-Intubation Sedation, Analgesia & Dissociative Maintenance 3.5 Transport Ventilator Setup & Primary Ventilation Modes
5 Chapter 3: Airway, Anesthesia, and Analgesics (Part 2)
3.6 Mechanical Ventilator Waveforms, Loops & Oxygenation Titration 3.7 Ventilator Alarm Troubleshooting & Peak vs Plateau Pressures 3.8 Rescue Airway Devices, Video Laryngoscopy & Surgical Cricothyrotomy 3.9 Neuromuscular Reversal & Vasoactive Airway Support 3.10 Transport Airway Management in Unique Environments & Extubation
6 Chapter 4: General Medical Patient
4.1 Sepsis, Severe Sepsis & Septic Shock Resuscitation 4.2 Endocrine Emergencies (DKA, HHS, Adrenal Crisis, Thyroid Storm) 4.3 Renal and Hepatic Emergencies in Transport
7 Chapter 5: Cardiac Patient
5.1 Acute Coronary Syndromes & Infarct Specific Complications 5.2 Invasive Hemodynamic Monitoring 5.3 Vasoactive & Inotropic Medication Titration 5.4 Mechanical Circulatory Support & Post-Cardiac Arrest Care
8 Chapter 6: Neurological Patient
6.1 Traumatic Brain Injury & Intracranial Pressure (ICP) Management 6.2 Acute Ischemic Stroke, Hemorrhagic Stroke & Subarachnoid Hemorrhage 6.3 Status Epilepticus, Spinal Cord Injury & Neurogenic Shock
9 Chapter 7: Respiratory Patient
7.1 Acute Respiratory Distress Syndrome (ARDS) & Lung-Protective Ventilation 7.2 Severe Asthma & COPD Exacerbations in Critical Care 7.3 Chest Tube Management, Pleural Drains & Tension Pneumothorax 7.4 Pulmonary Embolism, Pulmonary Hypertension & Transport Respiratory Meds
10 Chapter 8: Toxic Exposure and Environmental Patient
8.1 Toxicology Emergencies, Toxidromes & Antidote Therapy 8.2 Environmental Emergencies (Hypothermia, Hyperthermia, Frostbite) 8.3 Submersion, Diving Emergencies & Envenomation/HazMat
11 Chapter 9: Trauma and Burn Patient
9.1 Hemorrhagic Shock Resuscitation & Massive Transfusion Protocols (MTP) 9.2 Severe Thoracic & Abdominal Trauma Management 9.3 Thermal, Chemical & Electrical Burn Assessment & Fluid Resuscitation 9.4 Musculoskeletal Trauma, Pelvic Fractures & Compartment Syndrome
12 Chapter 10: Maternal and Fetal Medicine
10.1 High-Risk Obstetric Assessment & Hypertensive Disorders of Pregnancy 10.2 Obstetric Hemorrhage, Placental Abruption & Preterm Labor 10.3 Emergency Transport Delivery, Umbilical Cord Prolapse & Fetal Monitoring
13 Chapter 11: Pediatric Patient
11.1 Pediatric Critical Care Airway & Transport Ventilation 11.2 Pediatric Shock, Dehydration & Weight-Based Dosing 11.3 Neonatal Resuscitation Program (NRP) & Transport of the Critical Neonate
14 Chapter 12: Special Populations
12.1 Bariatric Critical Care Transport & Positional Management 12.2 Geriatric Critical Care & Patients with Specialized Medical Technology
15 Chapter 13: Professional Considerations
13.1 Legal Aspects, EMTALA & Transport Ethics 13.2 Quality Improvement, Transport Safety Research & Evidence-Based Practice
10.1 High-Risk Obstetric Assessment & Hypertensive Disorders of Pregnancy
Key Takeaways Explain This Topic AI
Maternal hypervolemia (+45% blood volume) causes physiological anemia, while decreased FRC (-20%) accelerates rapid arterial desaturation during airway management.
Aortocaval compression by the gravid uterus reduces cardiac output up to 30-40%; position all late-gestation patients in a left lateral tilt (15-30°) or perform manual left uterine displacement.
Severe preeclampsia is characterized by SBP ≥ 160 or DBP ≥ 110 with end-organ dysfunction; eclampsia is defined by the onset of tonic-clonic seizures.
Magnesium sulfate (4-6 g IV load over 15-20 min, then 1-2 g/hr) is first-line for eclamptic seizure control/prevention; toxic signs progress from loss of DTRs (8-10 mEq/L) to respiratory depression (10-12 mEq/L) and cardiac arrest (> 15 mEq/L).
Calcium gluconate 1 g IV over 3 minutes is the immediate antidote for magnesium sulfate toxicity.
Last updated: July 2026
- 10.1 High-Risk Obstetric Assessment & Hypertensive Disorders of Pregnancy
- Maternal Anatomical & Physiological Adaptations in Pregnancy
Managing the critically ill pregnant patient requires an intimate understanding of normal maternal physiological adaptations. During pregnancy, nearly every organ system undergoes dramatic functional changes designed to support fetal growth and prepare for labor. Failure to recognize these altered baselines can lead to misdiagnosis or inappropriate resuscitation in critical care transport.
Hematologic and Cardiovascular Adaptations
Blood Volume Expansion: Maternal intravascular blood volume increases by 45% above pre-pregnancy levels (typically an increase of 1500 mL 1500 \text{ mL} 1500 mL to 1800 mL 1800 \text{ mL} 1800 mL ). Plasma volume expands disproportionately by 40–50% , whereas red blood cell (RBC) volume increases by only 20–30% .
Physiological Anemia of Pregnancy: Because plasma volume expansion exceeds RBC mass expansion, hemodilution occurs. Normal third-trimester hemoglobin drops to 11.0 – 12.0 g/dL 11.0–12.0 \text{ g/dL} 11.0–12.0 g/dL and hematocrit falls to 32 – 34 % 32–34\% 32–34% .
Hemodynamic Parameters: Cardiac output (CO) increases by 30–50% (peaking at 28–32 weeks), driven by an increased stroke volume (+30%) and an elevated baseline resting heart rate (+10 to 15 beats/min). Simultaneously, Systemic Vascular Resistance (SVR) decreases by 20–30% due to smooth muscle relaxation induced by elevated circulating progesterone, prostacyclin, and nitric oxide.
Blood Pressure Trends: Systolic and diastolic blood pressures fall during the first and second trimesters (reaching a nadir at 24–28 weeks, typically 5 – 10 mmHg 5–10 \text{ mmHg} 5–10 mmHg below baseline) before gradually returning to pre-pregnancy baselines in the third trimester.
Hypercoagulable State: Pregnancy induces a hypercoagulable state characterized by increased clotting factors (factors VII, VIII, X, and fibrinogen) and decreased fibrinolytic activity, increasing the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) by 5-fold .
Parameter Pre-Pregnancy Baseline Third Trimester Value Clinical Significance for CCT
Blood Volume 4500 – 5000 mL 4500–5000 \text{ mL} 4500–5000 mL 6000 – 6500 mL 6000–6500 \text{ mL} 6000–6500 mL (+45%) Masks early signs of maternal hypovolemia; 1500 mL 1500 \text{ mL} 1500 mL blood loss before hypotension appears
Heart Rate 70 – 80 bpm 70–80 \text{ bpm} 70–80 bpm 80 – 95 bpm 80–95 \text{ bpm} 80–95 bpm (+10–15 bpm) Baseline tachycardia is physiological, but limits compensatory reserve
Blood Pressure 120 / 80 mmHg 120/80 \text{ mmHg} 120/80 mmHg Slight decrease or normal SBP ≥ 140 \ge 140 ≥ 140 or DBP ≥ 90 \ge 90 ≥ 90 is pathological in 3rd trimester
Hematocrit 37 – 48 % 37–48\% 37–48% 32 – 34 % 32–34\% 32–34% Physiological anemia; reduced oxygen-carrying capacity per mL
PaCO 2 \text{PaCO}_2 PaCO 2 35 – 45 mmHg 35–45 \text{ mmHg} 35–45 mmHg 27 – 32 mmHg 27–32 \text{ mmHg} 27–32 mmHg Compensated respiratory alkalosis ( HCO 3 − \text{HCO}_3^- HCO 3 − 18 – 22 mEq/L 18–22 \text{ mEq/L} 18–22 mEq/L )
FRC 2100 mL 2100 \text{ mL} 2100 mL 1600 mL 1600 \text{ mL} 1600 mL (-20–25%) Rapid desaturation during apnea/airway management
Respiratory Adaptations & Airway Risk
As the gravid uterus expands, it elevates the diaphragm by approximately 4 cm 4 \text{ cm} 4 cm , decreasing Functional Residual Capacity (FRC) by 20–25% . Concurrently, maternal oxygen consumption increases by 20% to meet fetal and metabolic demands.
Rapid Desaturation: During induction for rapid sequence intubation (RSI) or periods of apnea, pregnant patients desaturate catastrophically fast. Pre-oxygenation with 100 % FiO 2 100\% \text{ FiO}_2 100% FiO 2 for 3–5 minutes is critical.
Progesterone-Driven Hyperventilation: Elevated progesterone stimulates the respiratory center, increasing tidal volume by 30 – 40 % 30–40\% 30–40% and minute ventilation by 40 – 50 % 40–50\% 40–50% . This causes a physiological chronic respiratory alkalosis ( PaCO 2 = 27 – 32 mmHg \text{PaCO}_2 = 27–32 \text{ mmHg} PaCO 2 = 27–32 mmHg ) with renal metabolic compensation ( HCO 3 − = 18 – 22 mEq/L \text{HCO}_3^- = 18–22 \text{ mEq/L} HCO 3 − = 18–22 mEq/L ). A "normal" non-pregnant PaCO 2 \text{PaCO}_2 PaCO 2 of 40 mmHg 40 \text{ mmHg} 40 mmHg in a late-gestation patient indicates impending respiratory failure and severe hypercapnia!
Airway Edema: Upper airway mucosal hypervascularity and edema make the airway narrow, friable, and prone to bleeding. Use an endotracheal tube 0.5–1.0 mm smaller than standard (e.g., 6.0–6.5 mm ETT).
Aortocaval Compression & Positioning Management
After 20 weeks gestation, a patient placed in the supine position experiences aortocaval compression . The heavy gravid uterus compresses both the Inferior Vena Cava (IVC) against the lumbar spine and the abdominal aorta. [ Gravid Uterus ]
- │
- ▼ (Compresses in Supine Position)
- ┌─────────────────┴─────────────────┐
- ▼ ▼
- [ Inferior Vena Cava ] [ Abdominal Aorta ]
- │ │
- ▼ ▼
- Decreased Venous Return Decreased Uteroplacental
- │ & Lower Body Perfusion
- ▼ │
- Reduced Preload & Stroke Vol. │
- │ │
- ▼ ▼
- Drop in Cardiac Output (30-40%) ──► [ MATERNAL HYPOTENSION & FETAL DISTRESS ]
- Pathophysiology & Clinical Impact
Compression of the IVC severely impedes venous return to the heart, reducing maternal cardiac output by up to 30–40% .
This produces Supine Hypotensive Syndrome of Pregnancy , characterized by maternal tachycardia, dizziness, diaphoresis, nausea, and profound hypotension, leading directly to uteroplacental hypoperfusion and acute fetal bradycardia/distress.
Transport Positioning Protocols
Left Lateral Tilt: Position all pregnant patients past 20 weeks gestation in a 15 – 30 ∘ 15–30^\circ 15–3 0 ∘ left lateral tilt using a wedge, pillow, or rolled blanket placed under the right hip and spine.
Manual Left Uterine Displacement (LUD): If the patient is spinal-immobilized or undergoing cardiopulmonary resuscitation (CPR), perform manual LUD by using one or two hands to manually displace the uterus to the patient's left side away from the IVC. Manual LUD is essential during ACLS to restore effective CPR stroke volume!
Hypertensive Disorders of Pregnancy Spectrum
Hypertensive disorders complicate up to 10% of pregnancies worldwide and remain a leading cause of maternal and fetal mortality. [ MATERNAL HYPERTENSION (SBP ≥ 140 or DBP ≥ 90 after 20 wks) ]
- │
- ┌──────────────────────────────┴──────────────────────────────┐
- ▼ ▼
- [ NO Proteinuria & NO ] [ Proteinuria OR End-Organ ]
- [ End-Organ Dysfunction ] [ Dysfunction ]
- │ │
- ▼ ▼
- Gestational Hypertension Preeclampsia
- │
- ┌────────────────────────┴────────────────────────┐
- ▼ ▼
- [ Without Severe Features ] [ With Severe Features ]
- (SBP 140-159 / DBP 90-109) (SBP ≥ 160 or DBP ≥ 110,
- Severe Headache, RUQ Pain,
- Plts < 100k, Cr > 1.1)
- │
- ┌────────────────┴────────────────┐
- ▼ ▼
- Eclampsia HELLP Syndrome
- (New-Onset Seizures) (Hemolysis, Elevated LFTs,
- Low Platelets < 100k)
- Diagnostic Definitions
Gestational Hypertension:
Onset of SBP ≥ 140 mmHg \ge 140 \text{ mmHg} ≥ 140 mmHg or DBP ≥ 90 mmHg \ge 90 \text{ mmHg} ≥ 90 mmHg measured on two occasions at least 4 hours apart after 20 weeks gestation in a previously normotensive woman.
Absence of proteinuria and systemic end-organ signs.
Preeclampsia:
New-onset hypertension (SBP ≥ 140 mmHg \ge 140 \text{ mmHg} ≥ 140 mmHg or DBP ≥ 90 mmHg \ge 90 \text{ mmHg} ≥ 90 mmHg after 20 weeks) AND Proteinuria ( ≥ 300 mg \ge 300 \text{ mg} ≥ 300 mg in a 24-hour urine collection or urine protein/creatinine ratio ≥ 0.3 \ge 0.3 ≥ 0.3 ).
OR in the absence of proteinuria, new-onset hypertension accompanied by any of the following End-Organ Dysfunction indicators:
Thrombocytopenia: Platelet count < 100 , 000 / μ L < 100,000 / \mu\text{L} < 100 , 000/ μ L .
Renal Insufficiency: Serum creatinine > 1.1 mg/dL > 1.1 \text{ mg/dL} > 1.1 mg/dL or doubling of baseline.
Impaired Liver Function: Serum transaminases (AST/ALT) elevated to twice the upper limit of normal.
Pulmonary Edema.
New-Onset Cerebral or Visual Disturbances (severe persistent headache, scotomata, cortical blindness).
Preeclampsia with Severe Features:
SBP ≥ 160 mmHg \ge 160 \text{ mmHg} ≥ 160 mmHg or DBP ≥ 110 mmHg \ge 110 \text{ mmHg} ≥ 110 mmHg (confirmed 15 minutes apart).
Severe, persistent headache or visual disturbances refractory to analgesics.
Persistent severe epigastric or Right Upper Quadrant (RUQ) abdominal pain.
Progressive renal failure or severe thrombocytopenia.
Eclampsia:
Manifestation of new-onset generalized tonic-clonic seizures or unexplained coma in a pregnant or postpartum patient with preeclampsia, not attributable to underlying CNS pathology (e.g., stroke, intracranial hemorrhage).
HELLP Syndrome
HELLP syndrome is a life-threatening variant of severe preeclampsia present in 10–20% of severe preeclampsia cases.
H (Hemolysis): Microangiopathic hemolytic anemia. Endothelial disruption leads to fibrin deposition in microvessels, shredding red blood cells. Characterized by schistocytes on peripheral blood smear, elevated total bilirubin ( ≥ 1.2 mg/dL \ge 1.2 \text{ mg/dL} ≥ 1.2 mg/dL ), and significantly elevated Lactate Dehydrogenase (LDH > 600 U/L > 600 \text{ U/L} > 600 U/L ).
EL (Elevated Liver Enzymes): Microvascular thrombosis in liver sinusoids causes hepatic tissue ischemia, elevation of AST and ALT ( > 2 × > 2\times > 2 × upper limit of normal), and stretch of Glisson's capsule presenting as severe epigastric or RUQ pain.
LP (Low Platelets): Consumptive thrombocytopenia with platelet counts < 100 , 000 / μ L < 100,000 / \mu\text{L} < 100 , 000/ μ L due to widespread platelet activation and aggregation at damaged vascular endothelium.
Transport Risks & Management
High risk for spontaneous subcapsular hepatic hematoma formation and rupture , resulting in catastrophic intra-abdominal hemorrhage and rapid hypovolemic shock. Avoid palpating the liver vigorously.
Immediate transport to a tertiary perinatal facility for prompt C-section delivery, fluid/platelet resuscitation, and seizure prophylaxis.
Magnesium Sulfate Therapy & Toxicity Management
Magnesium sulfate ( MgSO 4 \text{MgSO}_4 MgSO 4 ) is the primary neuroprotective and anticonvulsant agent used to prevent eclamptic seizures in preeclampsia and terminate seizures in eclampsia. It acts as a central NMDA receptor blocker, cerebral vasodilator, and competitive calcium antagonist at the neuromuscular junction.
Dosing Protocols
Loading Dose: 4 – 6 g 4–6 \text{ g} 4–6 g IV diluted in 100 mL 100 \text{ mL} 100 mL D 5 W D_5W D 5 W or Lactated Ringer's, administered slowly over 15–20 minutes IV.
Maintenance Infusion: 1 – 2 g/hr 1–2 \text{ g/hr} 1–2 g/hr continuous IV infusion (diluted as 20 g 20 \text{ g} 20 g in 500 mL 500 \text{ mL} 500 mL LR or 40 g 40 \text{ g} 40 g in 1000 mL 1000 \text{ mL} 1000 mL LR).
Recurrent Seizure Protocol: If a seizure occurs while on magnesium, administer an additional 2 g 2 \text{ g} 2 g IV bolus over 3–5 minutes.
Therapeutic Serum Level: 4.0 – 7.0 mEq/L 4.0–7.0 \text{ mEq/L} 4.0–7.0 mEq/L ( 4.8 – 8.4 mg/dL 4.8–8.4 \text{ mg/dL} 4.8–8.4 mg/dL or 2.0 – 3.5 mmol/L 2.0–3.5 \text{ mmol/L} 2.0–3.5 mmol/L ).
Toxicity Monitoring Protocol
Critical care transport clinicians must assess deep tendon reflexes (patellar reflex), respiratory rate, and urine output every 15–30 minutes during transport. Serum Mg Level
- (mEq/L)
- ▲
- >15│ ─────────────────────────────────────── [ CARDIAC ARREST / ASYSTOLE ]
- │
- 10-12│ ─────────────────────────────────────── [ RESPIRATORY DEPRESSION (<12/min) / SOMNOLENCE ]
- │
- 8-10│ ─────────────────────────────────────── [ LOSS OF DEEP TENDON REFLEXES (PATELLAR) ]
- │
- 4-7│ ═══════════════════════════════════════ [ THERAPEUTIC RANGE (Seizure Prophylaxis) ]
- │
- └────────────────────────────────────────► Progressive Toxicity
Loss of Deep Tendon Reflexes (Patellar DTRs): Occurs at serum levels of 8 – 10 mEq/L 8–10 \text{ mEq/L} 8–10 mEq/L ( 9.6 – 12.0 mg/dL 9.6–12.0 \text{ mg/dL} 9.6–12.0 mg/dL ). This is the earliest reliable clinical warning sign of magnesium overdose!
Respiratory Depression: Respiratory rate drops below 12 breaths/min at 10 – 12 mEq/L 10–12 \text{ mEq/L} 10–12 mEq/L ( 12.0 – 14.4 mg/dL 12.0–14.4 \text{ mg/dL} 12.0–14.4 mg/dL ), accompanied by progressive somnolence and slurred speech.
Cardiac Conduction Defects & Arrest: Conduction delays, PR/QRS prolongation, severe heart block, and cardiac arrest occur at levels > 15 mEq/L > 15 \text{ mEq/L} > 15 mEq/L ( > 18.0 mg/dL > 18.0 \text{ mg/dL} > 18.0 mg/dL ).
Oliguria Warning: Because magnesium is excreted 100% by the kidneys, urine output must remain > 30 mL/hr > 30 \text{ mL/hr} > 30 mL/hr . Decreased renal clearance rapidly causes fatal magnesium accumulation.
Antidote Administration Protocol
If loss of reflexes or respiratory depression occurs:
Immediately STOP the magnesium sulfate infusion!
Administer Calcium Gluconate: 1 g 1 \text{ g} 1 g ( 10 mL 10 \text{ mL} 10 mL of a 10% solution) IV slow push over 3 minutes .
Alternative (if Calcium Gluconate unavailable): Calcium Chloride 500 – 1000 mg 500–1000 \text{ mg} 500–1000 mg ( 5 – 10 mL 5–10 \text{ mL} 5–10 mL of 10% solution) IV push slowly (preferably via central line to prevent severe tissue necrosis if extravasation occurs).
Provide bag-valve-mask (BVM) ventilation or endotracheal intubation as needed.
Acute Antihypertensive Therapy in Preeclampsia
Severe acute hypertension (SBP ≥ 160 mmHg \ge 160 \text{ mmHg} ≥ 160 mmHg or DBP ≥ 110 mmHg \ge 110 \text{ mmHg} ≥ 110 mmHg ) requires urgent pharmacologic reduction to prevent maternal hemorrhagic stroke and encephalopathy. The goal is to lower SBP to 140 – 150 mmHg 140–150 \text{ mmHg} 140–150 mmHg and DBP to 90 – 100 mmHg 90–100 \text{ mmHg} 90–100 mmHg without precipitous drops that compromise placental blood flow.
Antihypertensive Agent Mechanism of Action Adult Dosing Protocol Onset / Peak Contraindications & Precautions
Labetalol Selective α 1 \alpha_1 α 1 & non-selective β \beta β -blocker 20 mg 20 \text{ mg} 20 mg IV push over 2 min. If goal not reached, give 40 mg 40 \text{ mg} 40 mg at 10 min, then 80 mg 80 \text{ mg} 80 mg q10min (max 300 mg 300 \text{ mg} 300 mg ). Continuous IV infusion 1 – 2 mg/min 1–2 \text{ mg/min} 1–2 mg/min . Onset: 2–5 min; Peak: 5–15 min Contraindicated in asthma, active bronchospasm, severe bradycardia ( < 60 bpm <60 \text{ bpm} < 60 bpm ), or heart block ( > 1 ∘ >1^\circ > 1 ∘ ).
Hydralazine Direct arteriolar smooth muscle vasodilator 5 – 10 mg 5–10 \text{ mg} 5–10 mg IV push slowly over 2 min. Repeat 5 – 10 mg 5–10 \text{ mg} 5–10 mg IV q20min if needed (max total cumulative dose 30 mg 30 \text{ mg} 30 mg ). Onset: 10–20 min; Peak: 15–30 min Risk of unpredictable drop in blood pressure and reflex tachycardia; may mimic HELLP symptoms (nausea, headache).
Nifedipine (Immediate Release) L-type Calcium Channel Blocker 10 – 20 mg 10–20 \text{ mg} 10–20 mg PO orally. Repeat 10 – 20 mg 10–20 \text{ mg} 10–20 mg PO in 30 minutes if needed, then 10 – 20 mg 10–20 \text{ mg} 10–20 mg q2-6h. Onset: 10–20 min; Peak: 30–60 min First-line choice when IV access is unavailable. Do NOT give sublingually (causes uncontrolled, severe hypotensive collapse).